By Raechel Thankam Job and Richa Naidu July 30 (Reuters) – Sluggish European demand and weak respiratory sales raised doubts on Thursday about whether Haleon can meet its sales targets, sending shares
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)